Story perspectives

Trump's Drug Price Order Faces Skepticism and Opposition

5/13/2025

36 7

Summary

Story summary

President Trump signed an executive order to align U.S. drug prices with international rates, affecting pharmaceutical stocks.
Analysts express skepticism about immediate price reductions, labeling the order as ineffective.
The policy primarily targets drugs for Medicare and Medicaid, facing potential opposition from pharmaceutical companies.
The order focuses on direct-to-consumer pricing, which may adversely affect insurers and pharmacy benefit managers.

1 of 1

Story summary

President Trump signed an executive order to align U.S. drug prices with international rates, affecting pharmaceutical stocks.
Analysts express skepticism about immediate price reductions, labeling the order as ineffective.
The policy primarily targets drugs for Medicare and Medicaid, facing potential opposition from pharmaceutical companies.
The order focuses on direct-to-consumer pricing, which may adversely affect insurers and pharmacy benefit managers.